ILC2s: New Actors in Tumor Immunity

被引：36

作者：

Ercolano, Giuseppe ^{[1
]}

Falquet, Maryline ^{[1
]}

Vanoni, Giulia ^{[1
]}

Trabanelli, Sara ^{[1
]}

Jandus, Camilla ^{[1
]}

机构：

[1] Univ Lausanne, CHUV, Ludwig Inst Canc Res Lausanne, Dept Oncol, Lausanne, Switzerland

来源：

FRONTIERS IN IMMUNOLOGY | 2019年 / 10卷

基金：

瑞士国家科学基金会;

关键词：

patients; immunotherapy; cancer; ILC2; IL-33; ST2; INNATE LYMPHOID-CELLS; LUNG-CANCER; AMPHIREGULIN; INITIATION; INFLAMMATION; GUIDELINES; EFFECTOR; SYSTEM; GROWTH; ROLES;

D O I：

10.3389/fimmu.2019.02801

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Innate lymphoid cells (ILCs) represent the most recently identified family of innate lymphocytes that act as first responders, maintaining tissue homeostasis and protecting epithelial barriers. In the last few years, group 2 ILCs (ILC2s) have emerged as key regulators in several immunological processes such as asthma and allergy. Whilst ILC2s are currently being evaluated as novel targets for immunotherapy in these diseases, their involvement in tumor immunity has only recently begun to be deciphered. Here, we provide a comprehensive overview of the pleiotropic roles of ILC2s in different tumor settings. Furthermore, we discuss how different therapeutic approaches targeting ILC2s could improve the efficacy of current tumor immunotherapies.

引用

页数：9

共 112 条

[1] Targeting the TGFβ signalling pathway in disease [J].